These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22934253)

  • 1. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.
    Hooijkaas A; Gadiot J; Morrow M; Stewart R; Schumacher T; Blank CU
    Oncoimmunology; 2012 Aug; 1(5):609-617. PubMed ID: 22934253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BRAFV600E in an inducible murine model of melanoma.
    Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU
    Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
    Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
    Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
    Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
    McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
    J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
    Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
    J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
    Yuan P; Ito K; Perez-Lorenzo R; Del Guzzo C; Lee JH; Shen CH; Bosenberg MW; McMahon M; Cantley LC; Zheng B
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18226-31. PubMed ID: 24145418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
    Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
    Khalili JS; Liu S; Rodríguez-Cruz TG; Whittington M; Wardell S; Liu C; Zhang M; Cooper ZA; Frederick DT; Li Y; Zhang M; Joseph RW; Bernatchez C; Ekmekcioglu S; Grimm E; Radvanyi LG; Davis RE; Davies MA; Wargo JA; Hwu P; Lizée G
    Clin Cancer Res; 2012 Oct; 18(19):5329-40. PubMed ID: 22850568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
    White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
    Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib enhances MHC induction in BRAF
    Sapkota B; Hill CE; Pollack BP
    Oncoimmunology; 2013 Jan; 2(1):e22890. PubMed ID: 23483066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.
    Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X
    Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant Melanoma.
    Torres GM; Jarnagin HC; Park C; Yang H; Kosarek NN; Bhandari R; Wang CY; Kolling FW; Whitfield ML; Turk MJ; Liby KT; Pioli PA
    bioRxiv; 2023 Aug; ():. PubMed ID: 37577680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
    Oikonomou E; Koc M; Sourkova V; Andera L; Pintzas A
    PLoS One; 2011; 6(6):e21632. PubMed ID: 21738740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
    Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
    Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.